J
Juri Alessandro Giannotta
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 52
Citations - 644
Juri Alessandro Giannotta is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Autoimmune hemolytic anemia & Medicine. The author has an hindex of 9, co-authored 39 publications receiving 217 citations. Previous affiliations of Juri Alessandro Giannotta include University of Milan.
Papers
More filters
Journal ArticleDOI
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
TL;DR: A comprehensive review of the main clinical characteristics, diagnosis, and pathogenic mechanisms of AIHA are provided, along with classic and new therapeutic approaches.
Journal ArticleDOI
The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects
Bruno Fattizzo,Jessica Rosa,Jessica Rosa,Juri Alessandro Giannotta,Juri Alessandro Giannotta,Luca Baldini,Luca Baldini,Nicola Stefano Fracchiolla +7 more
TL;DR: The insight in the genomic landscape of the disease paves the way to the use of novel targeted drugs that might improve the outcome, particularly in relapse/refractory patients.
Journal ArticleDOI
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures
Wilma Barcellini,Juri Alessandro Giannotta,Juri Alessandro Giannotta,Bruno Fattizzo,Bruno Fattizzo +4 more
TL;DR: The severity of anemia at onset correlated with the recurrence of relapses, refractoriness, and fatal outcome reflects the presence of several mechanisms involved in AIHA, i.e. highly pathogenic antibodies, complement activation, and failure of marrow compensation.
Journal ArticleDOI
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers
Wilma Barcellini,Anna Zaninoni,Bruno Fattizzo,Juri Alessandro Giannotta,Monia Lunghi,Antonella Ferrari,Anna Paola Leporace,Nilla Maschio,Laura Scaramucci,Silvia Cantoni,Federico Chiurazzi,Dario Consonni,Giuseppe Rossi,Paolo de Fabritiis,Gianluca Gaidano,Alberto Zanella,Agostino Cortelezzi,Agostino Cortelezzi +17 more
TL;DR: A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER and the experience of the Oklahoma registry and the blood Center of Wisconsin shows promising results.
Journal ArticleDOI
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
Gianluigi Reda,Ramona Cassin,Gabriela Dovrtelova,Cristina Matteo,Juri Alessandro Giannotta,Maurizio D'Incalci,Agostino Cortelezzi,Massimo Zucchetti +7 more
TL;DR: Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy.